Lewis Karen's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Jan 31, 2024
- Accession no.
- 0001127602-24-002743
- Filed
- Jan 31, 2024
- Trade date
- Jan 29-30, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $81.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lewis KarenCIK 0001814304 | Officer (Chief People Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 29, 2024 | Common Stock | SSaleDisposed | −367 | $64.14 | −$23,539.38 | 47,270 | Direct | |
| Jan 30, 2024 | Common Stock | SSaleDisposed | −883 | $65.53 | −$57,862.99 | 46,387 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.